Business Targets
Visit Targets
49 source-backed visit targets across the Hong Kong / Shenzhen corridor and Greater Bay Area. Contact routes stay in your private pack.
Hong Kong
7 targetsBest Jul 6–7 or Jul 11 · avoid Jul 8–10 (LEAP East)
Great Bay Bio大湾生物
HKSTP-based 'AI + bioprocessing' company that applies AI to the manufacturing/CMC side of biologics — antibody design, cell-line development, culture-media optimization and sequence/expression optimization — i.e. the AI-in-biomanufacturing layer, not just AI drug discovery.
Next action: Prepare the private outreach route and meeting ask; keep contact details out of the app.
GenieBiome (G-NiiB)
CUHK clinician-scientist microbiome spinout behind the consumer G-NiiB probiotic brand — Hong Kong's most consumer-facing, clinically-credentialed microbiome company and the closest peer to a Coolvex-style functional-health play.
BioMed Technology Holdings
Hong Kong microbiome startup and HKSTP partner offering precision microbiome testing and probiotic products — and expanding into oral and skin microbiomes, the axis closest to Coolvex's topical-care focus.
BioMap百图生科
Baidu-backed 'large biology model' company whose 100B+-parameter life-science foundation model xTrimo powers an AI-Generated Protein (AIGP) platform — now standing up its first international innovation center, BioMap InnoHub, in Hong Kong with HK government (HKIC) backing.
Insilico Medicine英矽智能
End-to-end generative-AI drug discovery company, newly listed on HKEX, that both discovered and designed an oral IPF drug now heading to Phase III — with a parallel longevity/aging research agenda and an existing Gulf footprint.
GUTolution
A Hong Kong Science Park microbiome health-tech startup that runs an in-house sequencing lab, tests 5,000+ gut bacteria, and uses an AI engine to tailor-make and GMP-manufacture personalised probiotic formulas — the most relevant HK-based, consumer-facing precision-probiotic platform for a Week-1 Hong Kong meeting.
AilsynBio
HKU-spun-out, Science Park-based AI drug-design startup that fuses generative AI with physics-based modelling — and has signed a deal applying AI to traditional Chinese medicine.
Shenzhen
5 targetsFrom the Nanshan base · Jul 13–31
XtalPi晶泰科技
Shenzhen-founded, HK-listed quantum-physics-plus-AI drug discovery platform serving most of global big pharma — the Shenzhen counterpart to Insilico for AI-native discovery, and a strong platform-benchmarking peer.
BGI Genomics (GeneT / GBI ALL)华大基因（GeneT / 生成式生物智能）
Shenzhen-headquartered genomics giant whose GeneT (Genetic Transformer) multimodal genomic foundation model anchors its 'Generative Bio-Intelligence (GBI ALL)' paradigm — and which already runs a large AI-genomics operation inside Saudi Arabia (Genalive, Riyadh), making it the most Saudi-relevant company in this AI-biotech batch.
Xbiome未知君
Shenzhen clinical-stage, AI-driven microbiome drug developer that also does consumer-facing functional probiotics and strain licensing — the most credible China microbiome bridge to a consumer-health brand like Coolvex.
iCarbonX碳云智能
Shenzhen 'digital life' company building an AI platform that fuses multi-omics (genome, metabolome, microbiome) with lifestyle data to model individual health — an early, ambitious AI-multi-omics play whose mid-2010s hype has cooled and whose current momentum is unclear.
MegaRobo镁伽
A Beijing-headquartered embodied-AI-for-the-lab company fusing robotics automation and AI to build intelligent, self-running biological laboratories (MEGALAB) — the infrastructure layer under AI drug discovery, synthetic biology and bioprocess; included as a benchmark/ecosystem reference, with HQ in Beijing rather than the GBA.